Literature DB >> 21568232

Common sense treatment for common lipid disorders.

Mariko Johnson1, Clay F Semenkovich.   

Abstract

Dyslipidemia is a common, major modifiable risk factor for cardiovascular disease. Screening for lipid disorders is simple, and available treatments decrease disease risk. However, secondary causes of dyslipidemia are probably underappreciated, and severe lipid elevations should be referred to a lipid specialist. Patients usually respond to lifestyle modifications and drug therapy guided by a stepwise approach supported by the results of clinical trials, but several misconceptions may interfere with treatment strategies.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21568232      PMCID： PMC6189152     

Source DB:  PubMed          Journal:  Mo Med        ISSN： 0026-6620


  21 in total

1.  Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report.

Authors: 
Journal:  Circulation       Date:  2002-12-17       Impact factor: 29.690

2.  ACC/AHA/NHLBI clinical advisory on the use and safety of statins.

Authors:  Richard C Pasternak; Sidney C Smith; C Noel Bairey-Merz; Scott M Grundy; James I Cleeman; Claude Lenfant
Journal:  J Am Coll Cardiol       Date:  2002-08-07       Impact factor: 24.094

3.  Illuminating HDL--is it still a viable therapeutic target?

Authors:  Daniel J Rader
Journal:  N Engl J Med       Date:  2007-11-05       Impact factor: 91.245

4.  Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey.

Authors:  Earl S Ford; Wayne H Giles; William H Dietz
Journal:  JAMA       Date:  2002-01-16       Impact factor: 56.272

5.  Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.

Authors:  H B Rubins; S J Robins; D Collins; C L Fye; J W Anderson; M B Elam; F H Faas; E Linares; E J Schaefer; G Schectman; T J Wilt; J Wittes
Journal:  N Engl J Med       Date:  1999-08-05       Impact factor: 91.245

6.  Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study.

Authors:  Eric Bruckert; Gilles Hayem; Sylvie Dejager; Caroline Yau; Bernard Bégaud
Journal:  Cardiovasc Drugs Ther       Date:  2005-12       Impact factor: 3.727

7.  Efficacy and safety of rosuvastatin every other day compared with once daily in patients with hypercholesterolemia.

Authors:  Supakit Wongwiwatthananukit; Nakarin Sansanayudh; Rawadee Dhummauppakorn; Chutiporn Kitiyadisai
Journal:  Ann Pharmacother       Date:  2006-09-26       Impact factor: 3.154

8.  Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein.

Authors:  David J A Jenkins; Cyril W C Kendall; Augustine Marchie; Dorothea A Faulkner; Julia M W Wong; Russell de Souza; Azadeh Emam; Tina L Parker; Edward Vidgen; Karen G Lapsley; Elke A Trautwein; Robert G Josse; Lawrence A Leiter; Philip W Connelly
Journal:  JAMA       Date:  2003-07-23       Impact factor: 56.272

9.  Extended-release niacin or ezetimibe and carotid intima-media thickness.

Authors:  Allen J Taylor; Todd C Villines; Eric J Stanek; Patrick J Devine; Len Griffen; Michael Miller; Neil J Weissman; Mark Turco
Journal:  N Engl J Med       Date:  2009-11-15       Impact factor: 91.245

10.  Efficacy of alternate-day dosing versus daily dosing of atorvastatin.

Authors:  Mahtab Jafari; Ramin Ebrahimi; Mastaneh Ahmadi-Kashani; Harry Balian; Mohammad Bashir
Journal:  J Cardiovasc Pharmacol Ther       Date:  2003-06       Impact factor: 2.457
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.